<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352674</url>
  </required_header>
  <id_info>
    <org_study_id>IndonesiaU-01</org_study_id>
    <nct_id>NCT03352674</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label randomised multicenter clinical study to compare immunogenicity of the
      drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes
      mellitus patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous study has revealed that Insulin Glargine (Kalbe Farma) has similar efficacy with
      Lantus (Sanofi-Aventis) in controlling blood glucose in type 2 diabetes mellitus patients,
      but the immunogenicity potential of this product has not been known. Therefore, the present
      study is aiming to compare immunogenicity of Insulin Glargine (Kalbe Farma) and Lantus
      (Sanofi-Aventis) in type 2 diabetes mellitus patients in an open-label randomised multicenter
      clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of immune response</measure>
    <time_frame>6 months</time_frame>
    <description>Production of antibodies against insulin /IAA and ZnT8 antibody in investigational drug product and comparator groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>change in HbA1c level after 6 months of therapy compared to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Change in fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence and severity of hypoglycaemia cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine Ezelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine Lantus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Glargine Pen Injector [Lantus]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine Ezelin</intervention_name>
    <description>Insulin Glargine (Ezelin) once daily at individually adjusted dose</description>
    <arm_group_label>Insulin Glargine Ezelin</arm_group_label>
    <other_name>Ezelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine Pen Injector [Lantus]</intervention_name>
    <description>Insulin Glargine (Lantus) once daily at individually adjusted dose</description>
    <arm_group_label>Insulin Glargine Lantus</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women, 18 years old and above

          -  Diabetes mellitus type 2 patients who has failed an oral hypoglycemic drug products,
             insulin-naive, disease duration of at least 6 months, inadequate glycemic control
             (HbA1c &gt; 7.0 %)

          -  BMI ranged from 19 - 35 kg/m2

          -  Consent from patients of childbearing potential to use contraception method throughout
             the study

          -  Signed informed consent form

        Exclusion Criteria:

          -  History of diabetic ketoacidosis more than 2 times in the past 1 year

          -  History of pancreatectomy

          -  Estimated glomerular filtration rate &lt;30 mL/min

          -  Positive ZnT8 Antibody

          -  Treatment with glucocorticoids, immunodepressant or cytostatics in 60 days before
             study.

          -  Any malignant disease, including in medical history

          -  Drugs and alcohol abuse, including in medical history

          -  Hipersensitivity to insulin glargine or any excipient of the drugs from medical
             history

          -  Mental disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tri Juli Edi Tarigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cipto Mangunkusumo Hospital/Faculty of Medicine Universities Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melva Louisa, PhD</last_name>
    <email>melva.louisa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adisti Dwijayanti, MD</last_name>
    <email>adistimiltiades@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10520</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tri Juli Edi Tarigan, MD</last_name>
      <email>tje_tar@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Chakkarwar PN, Manjrekar NA. Insulin glargine: a long acting insulin analog. J Postgrad Med. 2005 Jan-Mar;51(1):68-71. Review.</citation>
    <PMID>15793346</PMID>
  </results_reference>
  <results_reference>
    <citation>McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs. 2001;61(11):1599-624. Review.</citation>
    <PMID>11577797</PMID>
  </results_reference>
  <results_reference>
    <citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr;19(2):327-36.</citation>
    <PMID>23598536</PMID>
  </results_reference>
  <results_reference>
    <citation>Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes. 2005 Dec;54 Suppl 2:S52-61. Review.</citation>
    <PMID>16306341</PMID>
  </results_reference>
  <results_reference>
    <citation>Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010 Jan;95(1):25-33. doi: 10.1210/jc.2009-1365. Epub 2009 Oct 29. Review.</citation>
    <PMID>19875480</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaziri-Sani F, Oak S, Radtke J, Lernmark K, Lynch K, Agardh CD, Cilio CM, Lethagen AL, Ortqvist E, Landin-Olsson M, TÃ¶rn C, Hampe CS. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity. 2010 Dec;43(8):598-606. doi: 10.3109/08916930903555927. Epub 2010 Mar 19.</citation>
    <PMID>20298127</PMID>
  </results_reference>
  <results_reference>
    <citation>Pan CY, Sinnassamy P, Chung KD, Kim KW; LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract. 2007 Apr;76(1):111-8. Epub 2006 Oct 2.</citation>
    <PMID>17011662</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005 Apr;28(4):950-5.</citation>
    <PMID>15793205</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008 Mar;51(3):408-16. doi: 10.1007/s00125-007-0911-x. Epub 2008 Jan 16.</citation>
    <PMID>18204830</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001 Apr;24(4):631-6.</citation>
    <PMID>11315821</PMID>
  </results_reference>
  <results_reference>
    <citation>Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005 Apr 9-15;365(9467):1333-46. Review.</citation>
    <PMID>15823385</PMID>
  </results_reference>
  <results_reference>
    <citation>Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006 Jun;29(6):1249-55.</citation>
    <PMID>16732004</PMID>
  </results_reference>
  <results_reference>
    <citation>Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.</citation>
    <PMID>15111519</PMID>
  </results_reference>
  <results_reference>
    <citation>Yki-JÃ¤rvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, LahdenperÃ¤ S, Nijpels G, VÃ¤hÃ¤talo M. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007 Jun;30(6):1364-9. Epub 2007 Mar 23.</citation>
    <PMID>17384341</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Dr Tri Juli Edi Tarigan, SpPD-KEMD</investigator_full_name>
    <investigator_title>Endocrinologist, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>insulin glargine</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

